Q2 2025 Celcuity Inc Earnings Call Transcript
Key Points
- Celcuity Inc (CELC) reported positive top-line data from the PIK3CA wild-type cohort of their Phase 3 VIKTORIA-1 clinical trial, showing significant improvement in progression-free survival (PFS) for gedatolisib combinations.
- The company achieved several milestones, including dosing the first patient in the Phase 3 VIKTORIA-1I trial and announcing favorable preliminary results from early-phase clinical trials.
- Celcuity Inc (CELC) extended patent exclusivity for gedatolisib into 2042, providing a long runway for development and commercialization.
- The company raised approximately $287 million through public offerings, ensuring sufficient funding for aggressive launch preparations pending FDA approval.
- Celcuity Inc (CELC) is on track to submit a new drug application to the FDA in the fourth quarter of 2025, with a promising market potential estimated at $5 billion for second-line therapy in breast cancer.
- Celcuity Inc (CELC) reported a net loss of $45.3 million for the second quarter of 2025, a significant increase from the previous year's loss.
- Research and development expenses rose substantially, driven by increased employee and consulting expenses, and costs related to ongoing clinical trials.
- General and administrative expenses also increased, reflecting higher employee and consulting costs and expanded infrastructure.
- The company faces a competitive landscape in the HR-positive, HER2-negative breast cancer space, with other therapies offering varying progression-free survival benefits.
- Celcuity Inc (CELC) must manage the complexities of launching gedatolisib independently, requiring significant investment in commercial infrastructure and market access strategies.
Good afternoon, ladies and gentlemen, and welcome to the Celcuity second-quarter 2025 financial results webcast and conference call. (Operator Instructions) I would now like to turn the conference over to Apoorva Chaloori with ICR Healthcare. Please go ahead.
Thank you, operator, and good afternoon to everyone. Thank you for joining us to review Celcuity's second-quarter 2025 financial results and business update. Earlier today, Celcuity Inc., released financial results for the second quarter ended June 30, 2025. The press release can be found on the Investor section of Celcuity's website.
Joining me on the call today are Brian Sullivan, Celcuity's Chief Executive Officer and Co-Founder; Vicky Hahne, Chief Financial Officer, as well as Igor Gorbachevsky, Chief Medical Officer, who will be available during Q&A.
Before we begin, I would like to remind listeners that our comments today will include some forward-looking statements. These statements involve a number of risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
